Jeffrey L Saver1. 1. Stroke Center and the Department of Neurology, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, USA. jsaver@ucla.edu
Abstract
BACKGROUND AND PURPOSE: Cerebral infarction is a leading cause of disability and death worldwide but has no uniform international definition. SUMMARY OF REVIEW: Recent diagnostic advances have revised fundamental concepts in cerebral and cardiac ischemia. Cardiologists, already possessed of a nosologic framework distinguishing myocardial infarction from unstable angina on the basis of tissue state, promulgated a new "universal" tissue definition of myocardial infarction incorporating insights afforded by assays of cardiac troponin, a serum biomarker exquisitely sensitive to myocardial injury. Concurrently, vascular neurologists proposed a new tissue, rather than time, criterion to distinguish transient ischemia attack from cerebral infarction, responding to perspectives provided by diffusion MRI and cerebral blood volume CT, imaging biomarkers highly sensitive to neuronal injury. To complete this conceptual realignment, vascular neurology must now advance a clear, uniform, and operationalizable tissue definition of cerebral infarction. This review proposes cerebral infarction be defined as brain or retinal cell death due to prolonged ischemia. This definition categorizes both pannecrosis and neuronal dropout ("complete" and "incomplete" infarcts in classic neuropathologic terminology) as cerebral infarcts. Making the presence of any neuronal or glial cell death essential yields a definition of cerebral infarction that has high relevance to patients, physicians, and policymakers; is more easily applied in clinical practice; fosters action in acute care; harmonizes with myocardial ischemia classification; and focuses diagnostic evaluation on the cause of brain ischemia and the occurrence of end organ injury. CONCLUSIONS: The term cerebral infarction should be used when there is evidence of brain or retinal cell death due to cerebral ischemia.
BACKGROUND AND PURPOSE:Cerebral infarction is a leading cause of disability and death worldwide but has no uniform international definition. SUMMARY OF REVIEW: Recent diagnostic advances have revised fundamental concepts in cerebral and cardiac ischemia. Cardiologists, already possessed of a nosologic framework distinguishing myocardial infarction from unstable angina on the basis of tissue state, promulgated a new "universal" tissue definition of myocardial infarction incorporating insights afforded by assays of cardiac troponin, a serum biomarker exquisitely sensitive to myocardial injury. Concurrently, vascular neurologists proposed a new tissue, rather than time, criterion to distinguish transient ischemia attack from cerebral infarction, responding to perspectives provided by diffusion MRI and cerebral blood volume CT, imaging biomarkers highly sensitive to neuronal injury. To complete this conceptual realignment, vascular neurology must now advance a clear, uniform, and operationalizable tissue definition of cerebral infarction. This review proposes cerebral infarction be defined as brain or retinal cell death due to prolonged ischemia. This definition categorizes both pannecrosis and neuronal dropout ("complete" and "incomplete" infarcts in classic neuropathologic terminology) as cerebral infarcts. Making the presence of any neuronal or glial cell death essential yields a definition of cerebral infarction that has high relevance to patients, physicians, and policymakers; is more easily applied in clinical practice; fosters action in acute care; harmonizes with myocardial ischemia classification; and focuses diagnostic evaluation on the cause of brain ischemia and the occurrence of end organ injury. CONCLUSIONS: The term cerebral infarction should be used when there is evidence of brain or retinal cell death due to cerebral ischemia.
Authors: Martin B Leon; Nicolo Piazza; Eugenia Nikolsky; Eugene H Blackstone; Donald E Cutlip; Arie Pieter Kappetein; Mitchell W Krucoff; Michael Mack; Roxana Mehran; Craig Miller; Marie-Angèle Morel; John Petersen; Jeffrey J Popma; Johanna J M Takkenberg; Alec Vahanian; Gerrit-Anne van Es; Pascal Vranckx; John G Webb; Stephan Windecker; Patrick W Serruys Journal: Eur Heart J Date: 2011-01-06 Impact factor: 29.983
Authors: Veena Hoffman; Jesper Hallas; Marie Linder; Andrea V Margulis; Brandon T Suehs; Alejandro Arana; Kelesitse Phiri; Cheryl Enger; Libby Horter; Ingvild Odsbu; Morten Olesen; Susana Perez-Gutthann; Yihua Xu; Nina Sahlertz Kristiansen; Kwame Appenteng; Stefan de Vogel; John D Seeger Journal: Drug Saf Date: 2021-07-08 Impact factor: 5.606
Authors: Tanja Djurdjevic; Rafael Rehwald; Michael Knoflach; Benjamin Matosevic; Stefan Kiechl; Elke Ruth Gizewski; Bernhard Glodny; Astrid Ellen Grams Journal: Eur Radiol Date: 2016-06-02 Impact factor: 5.315
Authors: Lorena Cristina Alvarez Sartor; Gustavo José Luvizutto; Juli Thomaz de Souza; Evelin Roberta Silva Dalle Molle; Gabriel Pinheiro Modolo; Taís Regina da Silva; Robson Aparecido Prudente; Priscila Watson Ribeiro; Rafael Dalle Molle da Costa; Letícia Cláudia de Oliveira Antunes; Natália Cristina Ferreira; Silméia Garcia Zanati Bazan; Fernanda Cristina Winckler; Hélio Rubens de Carvalho Nunes; Marcos Ferreira Minicucci; Rodrigo Bazan Journal: Rehabil Res Pract Date: 2020-02-03
Authors: Alejandro Arana; Andrea V Margulis; Cristina Varas-Lorenzo; Christine L Bui; Alicia Gilsenan; Lisa J McQuay; Maria Reynolds; Cristina Rebordosa; Billy Franks; Stefan de Vogel; Kwame Appenteng; Susana Perez-Gutthann Journal: Pharmacoepidemiol Drug Saf Date: 2020-10-28 Impact factor: 2.890